Showing 3881-3890 of 8198 results for "".
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- 'Dr. Pimple Popper' Offers Social Media Advicehttps://practicaldermatology.com/news/Dr-Pimple-Popper-Offers-Social-Media-Advice/2471209/Social media transformed Sandra Lee, MD, FAAD, FAACS, into “Dr. Pimple Popper.” While not every dermatologist aspires to have their own television show, many would like to maximize the impact of their social media presence, and Dr. Lee shared pearls from her own experience at the Winter Clinical
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://practicaldermatology.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Analysis: AI Sensor Reduces Scratching in Atopic Dermatitis Patientshttps://practicaldermatology.com/news/ai-sensor-reduces-scratching-in-atopic-dermatitis/2471104/A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports. Researchers for the single-arm, two-stage cohort study recruited 10 adults (60% female; mean age, 36) with at
- Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutishttps://practicaldermatology.com/news/Football-Star-OBJ-Raise-Awareness-Seborrheic-Dermatitis-With-Arcutis/2471099/NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced. “Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be do
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w